Sequencing of ponatinib-resistant LC-2/ad derivatives (PR1 and PR2) and parental LC-2/ad cells

Sequencing of ponatinib-resistant LC-2/ad derivatives (PR1 and PR2) and parental LC-2/ad cells was performed in order to determine mechanisms of acquired resistance in the PR1 and PR2 cell lines. NRAS p.Q61K mutation identified in PR1 cells. Upregulation of wild-type EGFR signaling identified in PR2 cells. Sequencing of ponatinib-resistant LC-2/ad derivatives (PR1 and PR2) and parental LC-2/ad cells was performed.

为明确普纳替尼（ponatinib）耐药的LC-2/ad衍生细胞系PR1、PR2以及亲本LC-2/ad细胞的获得性耐药机制，本研究对上述细胞进行了测序。在PR1细胞中鉴定出NRAS（Neuroblastoma RAS Viral Oncogene Homolog）基因p.Q61K突变。在PR2细胞中检测到野生型表皮生长因子受体（Epidermal Growth Factor Receptor, EGFR）信号通路的上调。本研究亦对普纳替尼耐药的LC-2/ad衍生细胞系PR1、PR2及亲本LC-2/ad细胞进行了测序。